TRIDESILON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIDESILON (TRIDESILON).
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
| Metabolism | Desonide is metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) to inactive metabolites. Topical application results in minimal systemic absorption, but extensive use on large areas or under occlusion can lead to sufficient systemic absorption for hepatic metabolism. |
| Excretion | Primarily hepatic metabolism; metabolites excreted renally (70%) and in feces (30%). |
| Half-life | 2–3 hours (topical); 1–2 hours (systemic) after IV, with clinical duration prolonged due to tissue binding. |
| Protein binding | 85–90%, primarily to albumin, less to alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.0–1.5 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Topical: minimal systemic absorption (∼1–5%); oral: not available; IM: 100%. |
| Onset of Action | Topical: 30 minutes – 1 hour; Intramuscular: 1–2 hours; Intravenous: rapid (minutes). |
| Duration of Action | Topical: 3–6 hours; Intramuscular: 6–12 hours; immediate-release IV: 2–3 hours. |
| Molecular Weight | 416.51 |
0.05% ointment or cream applied topically to affected area twice daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No adjustment necessary for topical use; systemic absorption is minimal. |
| Liver impairment | No adjustment necessary for topical use; systemic absorption is minimal. |
| Pediatric use | Use smallest amount effective; apply sparingly to affected area once or twice daily, not exceeding 2 weeks of continuous use. |
| Geriatric use | Use with caution due to thinner skin; apply sparingly to affected area once or twice daily for shortest duration necessary. |
| 1st trimester | Corticosteroids are generally avoided in first trimester unless benefits outweigh risks; increased risk of cleft palate reported in animal studies, but human data limited. Use only if clearly needed. |
| 2nd trimester | Use with caution; may cause fetal growth restriction and adrenal suppression with prolonged or high-dose use. Short-term, low-potency use preferred. |
| 3rd trimester | Use with caution near term; may cause maternal adrenal suppression and fetal hypothalamic-pituitary-adrenal axis suppression. Avoid if possible in last weeks. |
Clinical note
Comprehensive clinical and safety monograph for TRIDESILON (TRIDESILON).
| Placental transfer | Corticosteroids cross the placenta; degree varies by potency and formulation. Desonide (active ingredient) has low to moderate transfer, but high maternal doses may lead to fetal exposure. |
| Breastfeeding | Excretion into breast milk is minimal with topical use, but systemic absorption increases with large areas, occlusive dressings, or broken skin. Caution with prolonged or high-dose use. Use lowest effective dose for shortest duration. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to desonide or any component of formulationUntreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis)
| Precautions | Topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use or use on large body surface areas., Local adverse reactions include skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, and perioral dermatitis., Systemic effects such as Cushing's syndrome, hyperglycemia, and glucosuria can occur with extensive use., Not for ophthalmic use; contact dermatitis may occur. |
| Food/Dietary | No significant food interactions; avoid alcohol as it may worsen dizziness if present. |
Loading safety data…
| Lactation Rating | L3: Moderately Safe (limited data, potential for adverse effects with high doses or prolonged use) |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for major malformations when used in pregnancy, but systemic absorption can occur with extensive use. For Tridesilon (desonide), a low-potency corticosteroid, the risk is minimal. First trimester: No well-controlled studies; animal data suggest low risk. Second/Third trimester: Avoid prolonged use or large areas; may cause fetal growth restriction or adrenal suppression if significant systemic absorption. Overall, FDA Pregnancy Category C. |
| Fetal Monitoring | Monitor for signs of systemic absorption (adrenal suppression, Cushing's syndrome) if used extensively. For prolonged use or large areas, consider fetal growth surveillance. No specific fetal monitoring required for low-potency topical use. |
| Fertility Effects | No known adverse effects on fertility. Animal studies have not shown impairment. Human data are lacking. |
| Clinical Pearls | Tridesilon is a topical corticosteroid combination product (desonide and acetic acid) used for otitis externa. Avoid use in patients with perforated tympanic membrane due to risk of ototoxicity. Limited to 10 days of therapy. Clean ear canal before application. |
| Patient Advice | For external ear use only; do not put in eyes or mouth. · Shake bottle well before each use. · Fill ear canal with drops, stay lying down for 5 minutes with affected ear up. · Do not use if eardrum is perforated or if you have ear tubes. · Avoid water in ear during treatment; use earplugs when showering. · Complete full course even if symptoms improve. |